ABSTRACT
BACKGROUND: Screening of psychosocial risk factors for chronic low back pain (LBP) is essential. The Örebro Musculoskeletal Pain Screening Questionnaire (ÖMPSQ) is one of the most recognized and widely used instruments for this purpose. This study aimed to translate the ÖMPSQ into Persian, to adapt it for Iranian culture, and to investigate its psychometric properties. METHODS: Using a linguistic methodology, the ÖMPSQ was translated into Persian according to the World Health Organization guideline. A total of 106 patients with LBP participated in the study. Internal consistency and test-retest reliability were evaluated. Concurrent validity was estimated with Pearson's correlation between the ÖMPSQ and short form health survey (SF-12), Hospital Anxiety and Depression Scale (HADS), and visual analog scale (VAS). Factor analysis was used to evaluate dimensionality. RESULTS: The content validity index was 0.80. The instrument had a good test-retest reliability (intraclass correlation coefficient = 0.82) and internal consistency (Cronbach's α =0.82). Factor analysis indicates that factorial structure of Persian version was similar to original questionnaire. There was a significant correlation (r = 0.252-0.639, P < 0.01) between VAS score and all the ÖMPSQ domains. Physical component summary of SF-12 was positively correlated with miscellaneous domain (r = 384, P < 0.05) and negatively correlated with psychology domain of ÖMPSQ (r = -0.364, P < 0.05). A significant correlation between total score and anxiety component of HADS and psychology domain of ÖMPSQ was found (r = 0.49, P < 0.01 and r = 0.442, P < 0.05, respectively). Correlations between the ÖMPSQ and SF-12 and HADS and VAS indicate acceptable concurrent validity. CONCLUSIONS: The Persian version of ÖMPSQ was as a valid and reliable instrument and also a good cross-cultural equivalent for original English version.
ABSTRACT
SETTING: Some studies have reported a beneficial effect of zinc sulphate in children with community-acquired pneumonia (CAP). OBJECTIVE: To evaluate the effect of adjuvant zinc therapy in adult hospitalised CAP patients aged ⩾50 years on standard antibiotic treatment. METHODS: In a randomised double-blind placebo-controlled clinical trial, 91 hospitalised patients diagnosed with CAP using standard clinical and radiological criteria were randomised to receive 220 mg (110 mg twice daily) zinc sulphate for 4 days or placebo, in addition to antibiotics. The primary endpoint was length of hospital stay, and secondary endpoints were time to normalisation of oxygen saturation, respiratory rate and temperature. Disease severity was scored using CURB-65 (mental Confusion, Urea >20 mg/dl, Respiratory rate ⩾30/min, low Blood pressure and age ⩾65 years) RESULTS: The results did not show significant differences in length of hospital stay, time to normalisation of respiratory rate and oxygen saturation between patients in the zinc sulphate and placebo groups (P = 0.18, 0.65 and 0.26, respectively). CONCLUSION: A short course of zinc supplementation does not improve outcome in hospitalised patients aged ⩾50 years with CAP. In this setting, it should not be recommended as routine adjunctive treatment.